Table 2 MRI features and consistency analysis between the two HCC groups with cholangiocyte phenotype and non-cholangiocyte phenotype

Size (cm)

3.4 (1.0–17.1)

3.2 (0.8–20.0)

0.522

-

-

Tumor margin

 < 0.001

0.514

 < 0.001

 Smooth

22 (15.9%)

68 (34.7%)

 Non-smooth

116 (84.1%)

128 (65.3%)

Tumor growth subtype

0.163*

0.475

 < 0.001

 Single nodular type

50 (36.2%)

95 (48.5%)

 Single nodule type with Extra-nodular growth

77 (55.8%)

88 (44.9%)

 Contiguous multinodular type

4 (2.9%)

5 (2.5%)

 Infiltrative type

7 (5.1%)

8 (4.1%)

Marked diffusion restriction

0.244

0.570

 < 0.001

 Presence

28 (20.3%)

30 (15.3%)

 Absence

110 (79.7%)

166 (84.7%)

Marked T2 hyperintense

0.179

0.494

 < 0.001

 Presence

9 (6.5%)

6 (3.1%)

 Absence

129 (93.5%)

190 (96.9%)

Fat in mass more than liver

0.356

0.418

 < 0.001

 Presence

46 (33.3%)

76 (38.8%)

 Absence

92 (66.7%)

120 (61.2%)

Fat sparing in solid mass

0.801

0.481

 < 0.001

 Presence

8 (5.8%)

9 (4.6%)

 Absence

130 (94.2%)

187 (95.4%)

Non-rim APHE

 < 0.001

0.613

 < 0.001

 Presence

95 (58.8%)

179 (91.3%)

 Absence

43 (31.2%)

17 (8.7%)

Rim APHE

 < 0.001

0.574

 < 0.001

 Presence

45 (32.6%)

14 (7.1%)

 Absence

93 (67.4%)

182 (92.9%)

Internal artery

0.807

0.601

 < 0.001

 Presence

39 (28.3%)

59 (30.1%)

 Absence

99 (71.17%)

137 (69.9%)

Corona enhancement

0.220

0.547

 < 0.001

 Presence

70 (50.7%)

85 (43.4%)

 Absence

68 (49.3%)

111 (56.6%)

Nonperipheral washout

0.009

0.494

 < 0.001

 Presence

95 (68.8%)

160 (81.6%)

 Absence

43 (31.2%)

36 (18.4%)

Peripheral washout

0.004*

0.300

 < 0.001

 Presence

8 (5.8%)

1 (0.5%)

 Absence

130 (94.2%)

195 (99.5%)

Delayed central enhancement

 < 0.001

0.389

 < 0.001

 Presence

19 (13.8%)

6 (3.1%)

 Absence

119 (86.2%)

190 (96.9%)

PVP peritumoral hypo-enhancement

0.997

0.613

 < 0.001

 Presence

31 (22.5%)

44 (22.4%)

 Absence

107 (77.5%)

152 (77.6%)

Complete capsule

 < 0.001

0.538

 < 0.001

 Presence

18 (13.0%)

60 (30.6%)

 Absence

120 (87.0%)

136 (69.4%)

Blood products in mass

0.801

0.683

 < 0.001

 Presence

37 (26.8%)

50 (25.5%)

 Absence

101 (73.2%)

146 (74.5%)

Nodule in nodule

 < 0.001

0.412

 < 0.001

 Presence

81 (58.7%)

60 (30.6%)

 Absence

57 (41.3%)

136 (69.4%)

Mosaic architecture

0.029

0.552

 < 0.001

 Presence

51 (37.0%)

50 (25.5%)

 Absence

87 (63.0%)

146 (74.5%)

Infiltrative appearance

0.741

0.632

 < 0.001

 Presence

19 (13.8%)

24 (12.2%)

 Absence

119 (86.2%)

172 (87.8%)

Necrosis or severe ischemia

0.543

0.775

 < 0.001

 Presence

38 (27.5%)

61 (31.1%)

 Absence

100 (72.5%)

135 (68.9%)

Tumor in vein

0.822

0.786

 < 0.001

 Presence

8 (5.8%)

13 (6.6%)

 Absence

130 (94.2%)

183 (93.4%)

LI_RADS

0.129

0.412

 < 0.001

 4

12 (8.7%)

19 (9.7%)

 5

105 (76.1%)

161 (82.1%)

 M

21 (15.2%)

16 (8.2%)